Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

BACKGROUND: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Pungor, Katalin, Bozikas, Vasilis P., Emsley, Robin, Llorca, Pierre-Michel, Gopal, Srihari, Mathews, Maju, Wooller, Annette, Bergmans, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851108/
https://www.ncbi.nlm.nih.gov/pubmed/35186258
http://dx.doi.org/10.1177/2045125320981500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851108/
https://www.ncbi.nlm.nih.gov/pubmed/35186258
http://dx.doi.org/10.1177/2045125320981500

Ejemplares similares